SAN DIEGO, Calif., Sept. 26, 2019 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data from the
Phase 2 OASIS trial for etrasimod, an investigational, once-daily,
oral, selective sphingosine 1-phosphate (S1P) receptor modulator,
in development for a range of immune-mediated and inflammatory
conditions, including the ongoing ELEVATE UC Phase 3 trial
that was initiated this year. These data were presented at
the World Congress of Gastroenterology Meeting in Istanbul, Turkey.
"Steady-state etrasimod trough concentrations were achieved and
maintained from weeks 1 to 12 in patients with moderately to
severely active ulcerative colitis treated with 1 or 2 mg etrasimod
once-daily. Statistically significant exposure-response
relationships favoring 2 mg dosing were demonstrated, with
reductions from baseline in circulating lymphocyte count and
improvements in modified Mayo Clinic Score," stated Dr.
Preston Klassen, Executive Vice
President, Head of Research & Development at Arena. "In
addition to previously reported dose-response data from OASIS,
these new findings further strengthen the etrasimod 2 mg dosing
regimen chosen for our Phase 3 ELEVATE UC program."
Presentation Details:
Title: Steady-State
Trough Concentrations and Their Relationship to Selected
Demographic and Clinical Response Measures in Etrasimod-Treated
Patients With Moderately-to-Severely Active Ulcerative
Colitis
These data will be encored at the North American Society for
Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN)
2019 Annual Meeting, and the American Association of Pharmaceutical
Scientists (AAPS) 2019 PHARMSCI 360 Meeting.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
driven to deliver novel, transformational medicines with optimized
pharmacology to patients globally. Arena's proprietary pipeline
includes multiple potentially first- or best-in-class assets with
broad clinical utility. Etrasimod (APD334), with potential
utility in a broad range of immune-mediated and inflammatory
conditions, is being evaluated in later-stage clinical programs in
ulcerative colitis (UC) and Crohn's disease (CD), as well as in
programs for other indications such as atopic dermatitis. Arena is
also evaluating olorinab (APD371) in a Phase 2 program for
gastrointestinal pain. Arena continues to assess other earlier
research and development stage drug candidates, including APD418
for decompensated heart failure.
Arena has additional license agreements and partnerships,
including with United Therapeutics (ralinepag in a Phase 3 program
for pulmonary arterial hypertension), Everest Medicines Limited
(etrasimod in Greater China and
select Asian countries), Boehringer Ingelheim International GmbH
(undisclosed target – preclinical), Outpost Medicine, LLC
(undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai
Inc. (BELVIQ® – marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
identified by introductory words such as "in development for,"
"will," "driven to," "potentially," "potential," "evaluating," or
words of similar meaning, or by the fact that they do not relate
strictly to historical or current facts. Such forward-looking
statements include statements about Arena's participation in
upcoming meetings; the opportunity, development and potential of
etrasimod, including the dosing regimen in Arena's Phase 3 ELEVATE
UC Program; Arena's drive; and the potential of Arena's assets,
programs, licenses, and partnerships. For such statements, Arena
claims the protection of the Private Securities Litigation Reform
Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to
differ materially from the forward-looking statements include those
disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate Contact:
Kevin R.
Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-presented-new-data-from-the-phase-2-oasis-trial-for-etrasimod-at-the-world-congress-of-gastroenterology-meeting-300925709.html
SOURCE Arena Pharmaceuticals, Inc.